DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Obach, R. S.
Right arrow Articles by Reed-Hagen, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Obach, R. S.
Right arrow Articles by Reed-Hagen, A. E.

Vol. 30, Issue 7, 831-837, July 2002

Measurement of Michaelis Constants for Cytochrome P450-Mediated Biotransformation Reactions Using a Substrate Depletion Approach

R. Scott Obach and Anne E. Reed-Hagen

Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton, Connecticut

The Michaelis constant (KM) for cytochrome P450-mediated drug biotransformation reactions can be an important parameter in understanding the potential for a drug to exhibit saturable metabolism in vivo and nonlinear dose-exposure relationships. KM values were measured for several drug biotransformation reactions using recombinant heterologously expressed human enzymes. These determinations were made using an approach of monitoring substrate loss ("in vitro t1/2" method) at multiple substrate concentrations, with the objective of comparing KM values determined by this approach with KM values determined using the conventional approach of measuring product formation rates at several substrate concentrations. The reactions examined were CYP2C9-catalyzed diclofenac 4'-hydroxylation, CYP2D6-catalyzed dextromethorphan O-demethylation and thioridazine S-oxidation, CYP2C19-catalyzed imipramine N-demethylation, CYP3A4-catalyzed midazolam 1'-hydroxylation, and CYP1A2-catalyzed tacrine 1-hydroxylation. KM values spanned an 80-fold range from 0.12 µM (CYP2D6-catalyzed thioridazine S-oxidation) to 9.8 µM (CYP2C19-catalyzed imipramine N-demethylation). On average, KM values determined by the substrate depletion approach were within 1.54-fold of those determined by measuring product formation. Thus, KM values can be determined for drug metabolism reactions without requiring knowledge of metabolite structures or requiring authentic standards of metabolites for use in construction of standard curves for quantitative bioanalysis. The in vitro t1/2 approach of determining KM values should be useful in early drug discovery efforts to identify those compounds with low KM values and, hence, a greater probability of exhibiting supraproportional dose-exposure relationships.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
L. K. Chico, H. A. Behanna, W. Hu, G. Zhong, S. M. Roy, and D. M. Watterson
Molecular Properties and CYP2D6 Substrates: Central Nervous System Therapeutics Case Study and Pattern Analysis of a Substrate Database
Drug Metab. Dispos., November 1, 2009; 37(11): 2204 - 2211.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. Sjogren, H. Lennernas, T. B. Andersson, J. Grasjo, and U. Bredberg
The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CLint), Maximum Velocity of the Metabolic Reaction (Vmax), and Michaelis Constant (Km): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations
Drug Metab. Dispos., January 1, 2009; 37(1): 47 - 58.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Kotsuma, H. Hanzawa, Y. Iwata, K. Takahashi, and T. Tokui
Novel Binding Mode of the Acidic CYP2D6 Substrates Pactimibe and Its Metabolite R-125528
Drug Metab. Dispos., September 1, 2008; 36(9): 1938 - 1943.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. B. Yanni, P. P. Annaert, P. Augustijns, A. Bridges, Y. Gao, D. K. Benjamin Jr., and D. R. Thakker
Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes
Drug Metab. Dispos., June 1, 2008; 36(6): 1119 - 1125.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Zhang, D. Zhang, W. Li, M. Yao, C. D'Arienzo, Y.-X. Li, W. R. Ewing, Z. Gu, Y. Zhu, N. Murugesan, et al.
Reduction of Site-Specific CYP3A-Mediated Metabolism for Dual Angiotensin and Endothelin Receptor Antagonists in Various in Vitro Systems and in Cynomolgus Monkeys
Drug Metab. Dispos., May 1, 2007; 35(5): 795 - 805.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Nath and W. M. Atkins
A Theoretical Validation of the Substrate Depletion Approach to Determining Kinetic Parameters
Drug Metab. Dispos., September 1, 2006; 34(9): 1433 - 1435.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Dai, M. F. Hebert, N. Isoherranen, C. L. Davis, C. Marsh, D. D. Shen, and K. E. Thummel
EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
Drug Metab. Dispos., May 1, 2006; 34(5): 836 - 847.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Komura and M. Iwaki
NONLINEAR PHARMACOKINETICS OF PROPAFENONE IN RATS AND HUMANS: APPLICATION OF A SUBSTRATE DEPLETION ASSAY USING HEPATOCYTES FOR ASSESSMENT OF NONLINEARITY
Drug Metab. Dispos., June 1, 2005; 33(6): 726 - 732.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Isoherranen, K. L. Kunze, K. E. Allen, W. L. Nelson, and K. E. Thummel
ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION
Drug Metab. Dispos., October 1, 2004; 32(10): 1121 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. M. Jones and J. B. Houston
SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS
Drug Metab. Dispos., September 1, 2004; 32(9): 973 - 982.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Treijtel, A. Barendregt, A. P. Freidig, B. J. Blaauboer, and J. C. H. van Eijkeren
MODELING THE IN VITRO INTRINSIC CLEARANCE OF THE SLOWLY METABOLIZED COMPOUND TOLBUTAMIDE DETERMINED IN SANDWICH-CULTURED RAT HEPATOCYTES
Drug Metab. Dispos., August 1, 2004; 32(8): 884 - 891.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. L. Walsky and R. S. Obach
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
L. D. Saraswat, K. A. Caserta, K. Laws, D. Wei, S. S. Jones, and A. Adedoyin
A High-Throughput Method for Enzyme Kinetic Studies
J Biomol Screen, October 1, 2003; 8(5): 544 - 554.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Tamura, Y. Tokunaga, R. Ibuki, G. L. Amidon, H. Sezaki, and S. Yamashita
The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 310 - 316.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. S. Kalgutkar, S. Zhou, O. A. Fahmi, and T. J. Taylor
Influence of Lipophilicity on the Interactions of N-Alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and Their Positively Charged N-Alkyl-4-phenylpyridinium Metabolites with Cytochrome P450 2D6
Drug Metab. Dispos., May 1, 2003; 31(5): 596 - 605.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.